1. Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting Intravenous for Oral Busulfan in a Busulfan, Cyclophosphamide, and Etoposide Preparative Regimen 
Charu Aggarwal, Sameer Gupta, William P. Vaughan, Gene B. Saylors, Donna E. Salzman, Rhonda O. Katz, Amy G. Nance, Arabella B. Tilden, Matthew H. Carabasi 
Biology of Blood and Marrow Transplantation 
Volume 12, Issue 7, Pages (July 2006)
DOI: /j.bbmt
Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Schema for high-dose BuCyE preparative regimen for autoHSCT for NHL.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
(a) OS, (b) PFS, and (c) relapse rate after autoHSCT in 49 patients with intermediate-/high-risk NHL undergoing HSCT with PKD IV Bu in the BuCyE preparative regimen. AG indicates aggressive; Tx, treatment.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions